TNF-α and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn's disease and ulcerative colitis

Polskie Archiwum Medycyny Wewnetrznej

Volumn 122, Issue 12, 2012, Pages 616-623

  Owczarek, Danuta ^a   Cibor, Dorota ^a   Głowacki, Mikołaj K ^a   Cieśla, Andrzej ^a   Mach, Paweł ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Biomarkers; Crohn's disease; Inflammatory bowel diseases; Tumor necrosis factor receptors; Ulcerative colitis

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; ULCERATIVE COLITIS;

EID: 84872289433     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1537     Document Type: Article

References (27)

1. Baumgart DC. The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch Arztebl Int. 2009; 106: 123-133.
2. Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), arginine, and 8-iso-prostaglandin F2alpha (8-iso-PGF2alpha) level in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2010; 16: 52-57.
3. Rogler G. Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol. 2004; 20: 311-317. (Pubitemid 38813671)
4. Shi Y, Zhou EH, Wu HG, et al. Moxibustion treatment restoring the intestinal epithelium barrier in rats with Crohn's disease by down-regulating tumor necrosis factor alpha, tumor necrosis factor receptor 1, and tumor necrosis factor receptor 2. Chin J Integr Med. 2011; 17: 212-217.
5. Aslan M, Nazligu Y, Bolukbas C, et al. Peripheral lymphocyte DNA damage and oxidative stress in patients with ulcerative colitis. Pol Arch Med Wewn. 2011; 121: 223-229.
6. Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010; 20: 87-103.
7. Owczarek D, Cibor D, Szczepanek M, et al. Biological therapy of inflammatory bowel disease. Pol Arch Med Wewn. 2009; 119: 84-88.
8. Mizoguchi E, Mizoguchi A, Takedatsu H, et al. Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice. Gastroenterology. 2002; 122: 134-144. (Pubitemid 34049202)
9. Spoettl T, Hausmann M, Klebl F, et al. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm Bowel Dis. 2007; 13: 727-732. (Pubitemid 46909987)
10. Hadziselimovic F, Emmons LR, Gallati H. Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease. Gut. 1995; 37: 260-263.
11. Turan B, Pfister K, Diener PA, et al. Soluble tumour necrosis factor receptors sTNFR1 and sTNFR2 are produced at sites of inflammation and are markers of arthritis activity in Behçet's disease. Scand J Rheumatol. 2008; 37: 135-141. (Pubitemid 351536081)
12. Kaneyama K, Segami N, Sun W, et al. Levels of soluble cytokine factors in temporomandibular joint effusions seen on magnetic resonance images. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 99: 411-418. (Pubitemid 40379773)
13. Rojas-Cartagena C, Appleyard CB, Santiago OI, Flores I. Experimental intestinal endometriosis is characterized by increased levels of soluble TNFRSF1B and downregulation of Tnfrsf1a and Tnfrsf1b gene expression. Biol Reprod. 2005; 73: 1211-1218. (Pubitemid 41698611)
14. Hanai H, Watanabe F, Yamada M, et al. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol. 2004; 99: 1532-1538. (Pubitemid 39180103)
15. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol. 2007; 102: 2058-2069. (Pubitemid 47301524)
16. Grip O, Janciauskiene S, Bredberg A. Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease. Br J Pharmacol. 2008; 155: 1085-1092.
17. Gardiner KR, Halliday MI, Barclay GR. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut. 1995; 36: 897-901.
18. Kohut M, Kacperek-Hartleb T, Sojka D, Hartleb M. [Serum level of TNF-alpha receptor type II better correlates with severity of Crohn's disease than other cytokines and conventional clinical activity indicators]. Pol Merkur Lekarski. 2010; 28: 454-458. Polish.
19. Gustot T, Lemmers A, Louis E, et al. Profile of soluble cytokine receptors in Crohn's disease. Gut. 2005; 54: 488-495. (Pubitemid 40395500)
20. Stenson WF. Inflammatory bowel diseases. In: Yamada T, ed. Textbook of Gastroenterology. Vol. 2. 2nd Ed. Philadelphia, PE: JB Lippincott; 1995: 1761-1772.
21. Owczarek D, Cibor D, Sałapa K, et al. Anti-inflammatory and anticoagulant properties of the protein C system in inflammatory bowel disease. Pol Arch Med Wewn. 2012; 122: 209-216.
22. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55: 749-753. (Pubitemid 43764536)
23. Rentsch M, Beham A, Schlitt HJ, Jauch KW. Crohn's disease activity index and Vienna classification - is it worthwhile to calculate before surgery? Dig Surg. 2006; 23: 241-249. (Pubitemid 44651424)
24. van Deventer SJ, Tami JA, Wedel MK. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut. 2004; 53: 1646-1651. (Pubitemid 39434109)
25. Dzienis-Straczkowska S, Straczkowski M, Szelachowska M, et al. Soluble tumor necrosis factor-alpha receptors in young obese subjects with normal and impaired glucose tolerance. Diabetes Care. 2003; 26: 875-880. (Pubitemid 36929358)
26. González-Clemente JM, Giménez-Pérez G, Richart C, et al. The tumour necrosis factor (TNF)-alpha system is activated in accordance with pulse pressure in normotensive subjects with type 1 diabetes mellitus. Eur J Endocrinol. 2005; 153: 687-691. (Pubitemid 41672415)
27. Noguchi M, Hiwatashi N, Liu Z, et al. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut. 1998; 43: 203-209. (Pubitemid 28348322)